3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
Open Access
- 28 April 2021
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2020.00145
Abstract
Tenofovir alafenamide (TAF) has similar efficacy to tenofovir disoproxil fumarate (TDF) but with improved renal and bone safety in chronic hepatitis B patients studied outside of China. We report 3-year results from two phase 3 studies with TAF in China (Clinicaltrials.gov: NCT02836249 and NCT02836236).Keywords
This publication has 30 references indexed in Scilit:
- The global burden of liver disease: The major impact of ChinaJournal of Hepatology, 2014
- Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarateJournal of Hepatology, 2014
- FibroTest/Fibrosure for Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B: A Meta-AnalysisThe American Journal of Gastroenterology, 2014
- Tenofovir Alafenamide is Not a Substrate for Renal Organic Anion Transporters (Oats) and Does Not Exhibit Oat-Dependent CytotoxicityAntiviral Therapy, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2012
- Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapyJournal of Hepatology, 2012
- Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B VirusAntimicrobial Agents and Chemotherapy, 2006
- Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic TissueAntimicrobial Agents and Chemotherapy, 2005
- HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGSNucleosides, Nucleotides and Nucleic Acids, 2001